MitoRx Therapeutics Logo
Our Science
Pipeline
Our Team
SAB
News
Contact
HomeOur SciencePipelineOur TeamNewsContact

MitoRx Therapeutics appoints Xavier Jacq as CSO

1/5/2025

May 1, 2025

Harwell, Oxford, May 1, 2025, MitoRxTherapeutics Limited (MitoRx), a platform biotech company developing novel mitochondrial-targeted persulfide modifiers, today announces the appointment of Xavier Jacq as Chief Scientific Officer (CSO).

Xavier is a world-class scientist with extensive experience in small-molecule drug development and mitochondrial biology. He was most recently CSO at Moa Technologies in Oxford. Xavier previously held scientific leadership positions at Almac and Mission Therapeutics, and project leadership positions at Kudos and Sanofi. He has been a company founder, helping raise investment, building labs and drug discovery teams from scratch, and helping companies successfully exit through acquisition.

The new CSO significantly strengthens the MitoRx team as it builds towards clinical candidate nomination in its lead indication of the treatment of obesity and also develops a pipeline of discrete novel persulfide modifiers for a range of degenerative diseases.

“Welcoming Xavier to MitoRx cements our position as the leading biotech company developing mitochondrial-targeted therapeutics,” said Jon Rees, CEO, MitoRx.

“MitoRx is developing an innovative technology to restore mitochondrial metabolic pathways that are suppressed in a number of pathologies and in ageing. The prospect of being able to contribute to restoring metabolic function for patients with unmet medical needs is such an exciting opportunity that I had to join,” said Xavier Jacq, CSO, MitoRx. “MitoRx is a company with an enthusiastic and experienced team. This was also an essential factor in my decision to join MitoRx. We now have the potential to make a significant difference a large number of patients with degenerative diseases.”

For more information please contact:

Neil Hunter
Hunter PR
neiljameshunter@gmail.com
+44 7821 255568

About MitoRx

MitoRx’s mission is to develop a new class of medicine restoring normal metabolism by correcting impaired sulfide-signaling in obesity-related indications. Located in Harwell, Oxford, MitoRx has raised USD 8 million in seed financing from investors including the UK Innovation & Science Seed Fund, the Fink Family Office, Wren Capital, Oxford Technology Management, Empirical Ventures, the Science Angel Syndicate Network, Panacea Innovation Ventures, Longevitytech.fund, as well as angel investors. For more information, visit the website at mitorxtherapeutics.com and follow MitoRx on LinkedIn.

MitoRx Therapeutics Logo

Developing revolutionary mitochondrial-protective therapeutics which reverse mitochondrial dysfunction to arrest decline in muscular dystrophy and neurodegeneration.

Mail Icon

info@mitorxtherapeutics.com

Phone Icon

+44 1235 838631

Follow Us
About Us
HomeOur scienceOur teamContactNews
Legal
Privacy policyTerms of use
© Copyright 2021 MitoRx Therapeutics Limited - All Rights Reserved
9400 Garsington Road, Oxford Business Park Oxford OX4 2HN
Registered in England and Wales Company No. 13237941
Website by Stefan Benfield